Eculizumab in children with hemolytic uremic syndrome

David Kavanagh; Kate Smith-Jackson

doi:10.1016/j.kint.2015.12.039

Eculizumab in children with hemolytic uremic syndrome

Kidney Int. 2016 Mar;89(3):537-8. doi: 10.1016/j.kint.2015.12.039.

Authors

David Kavanagh¹, Kate Smith-Jackson²

Affiliations

¹ Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK. Electronic address: [email protected].
² Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.

PMID: 26880449
DOI: 10.1016/j.kint.2015.12.039

Abstract

Greenbaum et al. report the first prospective trial of eculizumab in pediatric atypical hemolytic uremic syndrome. As in adult trials, eculizumab appears effective and no serious safety signals were reported. There is the first suggestion of a dichotomy in response to treatment with a trend toward poorer outcome in those without complement abnormalities. This group, however, had worse renal function at presentation, and it remains to be seen whether this represents true non-response or merely late presentation.

Publication types

Comment

MeSH terms

Atypical Hemolytic Uremic Syndrome*
Child
Hemolytic-Uremic Syndrome*
Humans
Prospective Studies
Safety